Physician profile
Peter Rick Devuyst
NPI 1457369647
$11,948.91
in general payments reported to CMS, 2019-2025
36 companies · $2,990 in 2025
The $2,990 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,906 · 2022: $2,685 · 2023: $2,178 · 2024: $2,189 · 2025: $2,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,999 · Education: $335 · Consulting Fee: $24.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,999.33 |
| Education | $334.58 |
| Consulting Fee | $24.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,979.44 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $1,858.84 | 2021-2025 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $1,792.17 | 2021-2025 | Dupixent |
| Genzyme Corporation | $1,347.36 | 2021-2025 | |
| Csl Behring | $834.66 | 2022-2025 | Hizentra, Haegarda, Andembry |
| Amgen INC. | $797.34 | 2021-2025 | Tezspire |
| Grifols USA, LLC | $524.84 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Insmed, INC. | $393.83 | 2024-2025 | Arikayce, Brinsupri |
| Pharming Healthcare, INC. | $301.30 | 2021-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $273.36 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $227.13 | 2021-2025 | Cuvitru, Takhzyro, Hyqvia |
| Kaleo, INC. | $197.73 | 2021-2023 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $179.98 | 2022-2024 | |
| Biocryst US Sales Co., LLC | $177.34 | 2022-2025 | Orladeyo |
| Pfizer INC. | $116.59 | 2021-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $100.78 | 2022-2025 | Ayvakit |
| Nevro Corp. | $97.26 | 2023 | Senza |
| Genentech USA, INC. | $94.14 | 2021-2024 | Xolair |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.56 | 2024 | Lifevest |
| Cycle Pharmaceuticals INC | $64.93 | 2024-2025 | Sajazir |
| Teva Pharmaceuticals USA, INC. | $53.21 | 2021 | |
| Novo Nordisk INC | $50.80 | 2022 | |
| Lilly USA, LLC | $50.80 | 2025 | Ebglyss |
| Verona Pharma, INC. | $43.82 | 2025 | Ohtuvayre |
| Horizon Therapeutics Plc | $43.15 | 2021-2023 | Actimmune |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.09 | 2021 | |
| Merck Sharp & Dohme LLC | $32.96 | 2022-2023 | |
| Tersera Therapeutics LLC | $31.80 | 2023-2025 | Quzyttir |
| Galderma Laboratories, L.P. | $30.93 | 2025 | Nemluvio |
| Alk-Abello, INC | $27.94 | 2022 | |
| Ionis Pharmaceuticals, INC. | $25.82 | 2025 | Dawnzera |
| Adma Biomanufacturing LLC | $24.03 | 2025 | |
| Abbvie INC. | $23.56 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $18.27 | 2025 | Neffy |
| Vifor Pharma, INC. | $16.11 | 2025 | Zemaira |
| Optinose US, INC. | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Devuyst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.